A revised price target for Invesco Mortgage Capital (IVR) is prompting investors to reassess the mortgage REIT's trajectory amid evolving interest rate expectations and housing market dynamics.
Nutrien Ltd. (TSX:NTR) shares have climbed over 31% in the past year, prompting investors to question if the agricultural giant still presents a buying opportunity. A deep dive into valuation metrics suggests the stock may be fairly priced, but diverging narratives on future growth leave room for debate.
Shares in Canadian aerospace giant Bombardier plunged 9% following former U.S. President Donald Trump's threat to impose 50% tariffs and decertify its aircraft, escalating trade tensions and sparking alarm across the North American aviation industry.
While mortgage rates have inched up slightly this week, homebuyers are still facing significantly lower borrowing costs compared to last year's peak. We break down the monthly and long-term savings on a typical home purchase.
Exclusive footage and soldier testimonies reveal a disturbing pattern within Russian ranks: wounded amputees, including former prisoners, are being ordered back into combat as casualties mount and manpower dwindles.
Secretary-General Antonio Guterres warns in a confidential letter that the United Nations faces a severe cash crunch, driven by unpaid dues and restrictive budget rules, threatening its operational viability by mid-year.
The NBA's Minnesota Timberwolves have released a public statement calling for community solidarity following two separate fatal shootings involving federal immigration agents in Minneapolis, which have sparked protests and renewed debate over immigration enforcement.
As hearings conclude at the UN's highest court, Rohingya refugees express cautious hope for a landmark genocide ruling against Myanmar, a decision with potential global legal ramifications.
Rosenblatt Securities initiates coverage on Credo Technology with a Neutral rating and a $170 price target, highlighting its strong position in high-speed connectivity for AI infrastructure while flagging competitive pressures. The note follows a more bullish target hike from Barclays earlier in the month.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
B.Riley initiates coverage on BrightSpire Capital (BRSP) with a Buy rating, highlighting its robust cash position and improved credit quality as key drivers for future loan originations, while its stock trades at a discount to book value.
ARMOUR Residential REIT (ARR) received a bullish upgrade from Jones Trading, which moved the stock to Buy with a $20.50 target, citing a discounted valuation and expected book value growth compared to agency mortgage REIT rivals.
Analysts at BTIG have upgraded mortgage REIT Annaly Capital Management (NLY) from 'Neutral' to 'Buy', with a $25 price target, arguing the stock is positioned to benefit from dividend stability and potential spread movements in a turbulent interest rate landscape.
SharpLink Gaming (NASDAQ: SBET) is drawing bullish attention from major Wall Street firms, with multiple analysts reiterating Buy ratings. The company's substantial Ethereum holdings and management's crypto expertise are seen as key drivers, even as price targets adjust to market conditions.
Innodata Inc. (NASDAQ: INOD), a data engineering and AI services firm, has been awarded a place on a critical U.S. Missile Defense Agency contract vehicle, positioning it for future task orders in defense technology development and fueling analyst optimism for its 2026 growth trajectory.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
Iran's foreign minister stated readiness for 'fair' negotiations with Washington but firmly ruled out discussing its defense capabilities, as regional powers intensify diplomacy to avert a military confrontation.
Truist Securities has slightly lowered its price target on Tesla shares to $438, citing the significant capital expenditure required for the automaker's aggressive shift towards AI and robotics, despite a solid Q4 performance.
Investment firm TD Cowen has increased its price target on Tesla (TSLA) to $519, maintaining a Buy rating. The adjustment follows a fourth-quarter performance marked by strong margins and progress on autonomous driving projects, though tempered by higher capital expenditure forecasts and vague timelines for full self-driving technology.
